Literature DB >> 24783039

Ki-67 labeling index is a predictor of postoperative persistent disease and cancer growth and a prognostic indicator in papillary thyroid carcinoma.

Akira Miyauchi1, Takumi Kudo2, Mitsuyoshi Hirokawa3, Yasuhiro Ito1, Minoru Kihara1, Takuya Higashiyama1, Tomonori Yabuta1, Hiroo Masuoka1, Hisakazu Shindo1, Kaoru Kobayashi1, Akihiro Miya1.   

Abstract

BACKGROUND: We previously reported that the Ki-67 labeling index (LI) in primary tumors and the thyroglobulin (Tg)-doubling time (DT) were potent prognostic indicators in patients with papillary thyroid carcinoma (PTC).
OBJECTIVES: To elucidate the relationship between these two factors.
METHODS: A total of 390 patients with PTC who underwent total thyroidectomy between 1998 and 2004 and in whom the Tg-DT was calculated were enrolled. We determined the Ki-67 LI in primary tumors and compared these values with the patients' clinicopathological factors, postoperative Tg status, Tg-DT, and prognosis. Tg status was categorized by postoperative serum Tg values: biochemically persistent disease (BPD), equivocal state, and biochemical remission.
RESULTS: The Ki-67 LI was ≤5% in 312 patients (80%), 5%-10% in 48 patients (12%), and >10% in 30 patients (8%). Ki-67 LI was significantly associated with BPD (p < 0.0001). The proportion of BPD patients increased with the higher Ki-67 LI category: 24, 67, and 87%, respectively. The Ki-67 LI had a significant inverse correlation with the Tg-DT (Spearman's ρ = -0.5267, p < 0.0001). Of the 378 patients without distant metastasis at surgery, 68 patients had recurrence, and 6 of the 390 patients died of PTC during the follow-up (mean 88 months). On multivariate analyses, the Ki-67 LI remained an independent predictor of disease-free survival and disease-specific survival when Tg-DT and Tg status were excluded from the analyses.
CONCLUSIONS: Evaluation of the Ki-67 LI in primary tumors may allow the prediction of the postoperative Tg status, Tg-DT and prognosis of patients with PTC. Published by S. Karger AG, Basel.

Entities:  

Keywords:  Biochemically persistent disease; Ki-67 labeling index; Papillary thyroid carcinoma; Prognosis; Thyroglobulin-doubling time

Year:  2013        PMID: 24783039      PMCID: PMC3821500          DOI: 10.1159/000347148

Source DB:  PubMed          Journal:  Eur Thyroid J        ISSN: 2235-0640


  19 in total

1.  Undetectable serum thyroglobulin levels in patients with medullary thyroid carcinoma after total thyroidectomy without radioiodine ablation.

Authors:  Chisato Tomoda; Akira Miyauchi
Journal:  Thyroid       Date:  2012-06-04       Impact factor: 6.568

2.  Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67.

Authors:  J Gerdes; L Li; C Schlueter; M Duchrow; C Wohlenberg; C Gerlach; I Stahmer; S Kloth; E Brandt; H D Flad
Journal:  Am J Pathol       Date:  1991-04       Impact factor: 4.307

Review 3.  Staging systems for papillary thyroid carcinoma: a review and comparison.

Authors:  Brian Hung-Hin Lang; Chung-Yau Lo; Wai-Fan Chan; King-Yin Lam; Koon-Yat Wan
Journal:  Ann Surg       Date:  2007-03       Impact factor: 12.969

4.  Death from thyroid cancer of follicular cell origin.

Authors:  H S Wu; M T Young; P H Ituarte; A D'Avanzo; Q Y Duh; F S Greenspan; K C Loh; O H Clark
Journal:  J Am Coll Surg       Date:  2000-12       Impact factor: 6.113

5.  Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma.

Authors:  A Miyauchi; T Onishi; S Morimoto; S Takai; F Matsuzuka; K Kuma; M Maeda; Y Kumahara
Journal:  Ann Surg       Date:  1984-04       Impact factor: 12.969

Review 6.  Prognostic factors and therapeutic strategies for differentiated carcinomas of the thyroid.

Authors:  Yasuhiro Ito; Akira Miyauchi
Journal:  Endocr J       Date:  2008-08-13       Impact factor: 2.349

7.  Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.

Authors:  K C Loh; F S Greenspan; L Gee; T R Miller; P P Yeo
Journal:  J Clin Endocrinol Metab       Date:  1997-11       Impact factor: 5.958

8.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; S M Jhiang
Journal:  Am J Med       Date:  1994-11       Impact factor: 4.965

Review 9.  Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review.

Authors:  Elisabeth Luporsi; Fabrice André; Frédérique Spyratos; Pierre-Marie Martin; Jocelyne Jacquemier; Frédérique Penault-Llorca; Nicole Tubiana-Mathieu; Brigitte Sigal-Zafrani; Laurent Arnould; Anne Gompel; Caroline Egele; Bruno Poulet; Krishna B Clough; Hubert Crouet; Alain Fourquet; Jean-Pierre Lefranc; Carole Mathelin; Nicolas Rouyer; Daniel Serin; Marc Spielmann; Margaret Haugh; Marie-Pierre Chenard; Etienne Brain; Patricia de Cremoux; Jean-Pierre Bellocq
Journal:  Breast Cancer Res Treat       Date:  2011-11-03       Impact factor: 4.872

10.  Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study.

Authors:  D M Berney; A Gopalan; S Kudahetti; G Fisher; L Ambroisine; C S Foster; V Reuter; J Eastham; H Moller; M W Kattan; W Gerald; C Cooper; P Scardino; J Cuzick
Journal:  Br J Cancer       Date:  2009-03-24       Impact factor: 7.640

View more
  14 in total

1.  Prognostic Significance of the Proportion of Tall Cell Components in Papillary Thyroid Carcinoma.

Authors:  Yasuhiro Ito; Mitsuyoshi Hirokawa; Akira Miyauchi; Takuya Higashiyama; Minoru Kihara; Akihiro Miya
Journal:  World J Surg       Date:  2017-03       Impact factor: 3.352

2.  Study of Immunohistochemical Markers (CK-19, CD-56, Ki-67, p53) in Differentiating Benign and Malignant Solitary Thyroid Nodules with special Reference to Papillary Thyroid Carcinomas.

Authors:  Smriti Sudhanshu Dwivedi; Siddhi Gaurish Sinai Khandeparkar; Avinash R Joshi; Maithili Mandar Kulkarni; Pallavi Bhayekar; Amruta Jadhav; Musphera Nayar; Neelam S Kambale
Journal:  J Clin Diagn Res       Date:  2016-12-01

3.  Characteristics of neck level VI lymph nodes in papillary thyroid carcinoma: correlation between nodal characteristics and primary tumor.

Authors:  Jung-Soo Pyo; Jin Hee Sohn; Guhyun Kang; Dong-Hoon Kim; Dong Hyun Kim
Journal:  Endocr Pathol       Date:  2015-03       Impact factor: 3.943

4.  Value of Ultrasound Combined with Immunohistochemistry Evaluation of Central Lymph Node Metastasis for the Prognosis of Papillary Thyroid Carcinoma.

Authors:  Xiaohua Yao; Ying Meng; Runsheng Guo; Guofeng Lu; Lin Jin; Yingchun Wang; Debin Yang
Journal:  Cancer Manag Res       Date:  2020-09-22       Impact factor: 3.989

5.  Airtight tracheocutaneostomy after window resection of the trachea for invasive papillary thyroid carcinoma: experience of 109 cases.

Authors:  Yasuhiro Ito; Akira Miyauchi; Minoru Kihara; Takuya Higashiyama; Kaoru Kobayashi; Akihiro Miya
Journal:  World J Surg       Date:  2014-03       Impact factor: 3.352

Review 6.  American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment.

Authors:  David C Shonka; Alan Ho; Ashish V Chintakuntlawar; Jessica L Geiger; Jong C Park; Nagashree Seetharamu; Sina Jasim; Amr H Abdelhamid Ahmed; Keith C Bible; Marcia S Brose; Maria E Cabanillas; Kirsten Dabekaussen; Louise Davies; Dora Dias-Santagata; James A Fagin; William C Faquin; Ronald A Ghossein; Raj K Gopal; Akira Miyauchi; Yuri E Nikiforov; Matthew D Ringel; Bruce Robinson; Mabel M Ryder; Eric J Sherman; Peter M Sadow; Jennifer J Shin; Brendan C Stack; R Michael Tuttle; Lori J Wirth; Mark E Zafereo; Gregory W Randolph
Journal:  Head Neck       Date:  2022-03-11       Impact factor: 3.821

7.  TERT promoter mutations and Ki-67 labeling index as a prognostic marker of papillary thyroid carcinomas: combination of two independent factors.

Authors:  Michiko Matsuse; Tomonori Yabuta; Vladimir Saenko; Mitsuyoshi Hirokawa; Eijun Nishihara; Keiji Suzuki; Shunichi Yamashita; Akira Miyauchi; Norisato Mitsutake
Journal:  Sci Rep       Date:  2017-02-02       Impact factor: 4.379

8.  p63 inhibits CD44+/CD24- cell proliferation and chemoresistance in papillary thyroid carcinoma cells.

Authors:  Jing-Jing Guo; Hong-Shun Xu; Gang Wu; Zhen-Yu Ma
Journal:  Exp Ther Med       Date:  2017-09-19       Impact factor: 2.447

Review 9.  The diagnostic and prognostic values of Ki-67/MIB-1 expression in thyroid cancer: a meta-analysis with 6,051 cases.

Authors:  Deng-Hua Pan; Dong-Yue Wen; Yi-Huan Luo; Gang Chen; Hong Yang; Jun-Qiang Chen; Yun He
Journal:  Onco Targets Ther       Date:  2017-07-03       Impact factor: 4.147

10.  The clinicopathological significance of Ki67 in papillary thyroid carcinoma: a suitable indicator?

Authors:  Jingdong Tang; Chunyi Gui; Shenglong Qiu; Min Wang
Journal:  World J Surg Oncol       Date:  2018-05-31       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.